Study of the diagnostic value of the serum level of the marker SCCA in esophageal squamous cell carcinoma
N K Parilova , N S Sergeeva , N V Marshutina , A S Mamontov , V G Vereshchagin , M P Solokhina , I S Meysner , N K Parilova , N S Sergeyeva , N V Marshutina , A S Mamontov , V G Vereshchagin , M P Solokhina , I S Meisner
Russian Journal of Oncology ›› 2011, Vol. 16 ›› Issue (4) : 40 -42.
Study of the diagnostic value of the serum level of the marker SCCA in esophageal squamous cell carcinoma
The level of a serological marker for squamous cell carcinomas (SCC) was studied in patients with primary, remitting, and relapsing esophageal SCC (ESCC). The levels of SCC antigen (SCCA) increased from Stage I to Stage IV (from 0.8±0.3 to 1.7±0.3 ng/ml, so as the percentage of patients with elevated SCCA (from 20 to 60%, respectively). In remission, the values of SCCA were within the upper normal range in all the patients. The diagnostic sensitivity of SCCA in relapse was similar to that in primary SCC (38/9 and 39.8%, respectively). The proportion of SCCA-positive cases was higher in patients with low- and moderate-grade tumors than in those with high-grade tumors (54.1 and 21.4% of cases, respectively). The mean level of SCCA slightly rose after invasive diagnostic procedures. Hence, this group of patients should undergo serum SCCA tests before and 3-4 days after invasive diagnostic procedures. For the monitoring of the efficiency of treatment and preclinical detection of relapses, it is expedient to use SCCA as a serological marker in 30-40% of all patients with primary ESCC and in approximately 50% of patients with low- and moderate-grade SCC.
SCC / serological tumor-associated markers / squamous cell carcinoma / esophageal squamous cell carcinoma
| [1] |
Сергеева Н. С., Дубовецкая О. Б., Маршутина Н. В. и др. // Рос. онкол. журн. - 2004. - № 4. - С. 12-14. |
| [2] |
Сергеева Н. С., Дубовецкая О. Б., Мпршутина Н. В. и др. // Рос. онкол. журн. - 2004. - № 2. - С. 37-39. |
| [3] |
Сергеева Н. С., Маршутина Н. В., Трахтенберг А. Х. и др. // Рос. онкол. журн. - 2010. - № 3. |
| [4] |
Cataltepe S., Luke C., Silverman G. et al. // Tumor Biol. - 2002. - Vol. 23. - P. 17. |
| [5] |
Crombach G., Scharl A., Vierbuchen M. et al. // Cancer. - 1989. - Vol. 63, N 7. - P. 1337-1342. |
| [6] |
Hefler L., Obermair A., Tempfler C. et al. // Int J. Cancer. - 1999. - Vol. 84, N 3. - P. 299-303. |
| [7] |
Ikeda K. // Nippon Geka Gakkai Zasshi. - 1991. - Vol. 92, N 4. - P. 387-396. |
| [8] |
Kato H. // Anticancer Res. - 1996. - Vol. 16, N 48. - P. 2149-2153. |
| [9] |
Koch T., Eiffert H., Spindler M. // HNO. - 1989. - Bd 37, N 11. - S. 454-459. |
| [10] |
Nilsson O., Roijer E., Nilsson K. // Tumor Biol. - 2002. - Vol. 23. - P. 15. |
| [11] |
Roijer E., Kosinska U., Andersson J. et al. // Tumor Biol. - 1998. - Vol. 19. - P. 84. |
| [12] |
Roijer E., Kosinska U., Andersson J. et al. // Tumor Biol. - 2003. - Vol. 24. - P. 46-52. |
| [13] |
Rosati G., Riccardi F., Tucci A. // Int. J. Bol. Markers. - 2000. - Vol. 15, N 2. - P. 179-183. |
| [14] |
Sanchez-de-Cos-Escuin J., Lopez-Parra S., Desdier-Vicente C. et al. // An. Med. Interna. - 1996. - Vol. 13, N 8. - P. 369- 373. |
| [15] |
Takeshi M., Shigeki Y., Takashi S. et al. // Tumor Biol. - 1998. - Vol. 19. - P. 494-504. |
| [16] |
Van Dalen A. // Anticancer Res. - 1996. - Vol. 16, N 4. - P. 2345-2349. |
| [17] |
van der Sijde R., de Bruijn H., Kraws M. et al. // Gynecol. Oncol. - 1989. - Vol. 35, N 2. - P. 227-232. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
